Zeina A Al-Mansour, M.D.
Associate Professor
Department:
MD-HEMATOLOGY/ONCOLOGY
Business Phone:
(352) 273-7832
Business Email:
zeina.almansour@ufl.edu
About Zeina A Al-Mansour
Zeina Al-Mansour, MD, is an associate professor in UF Health’s Division of Hematology & Oncology in the University of Florida College of Medicine.
Dr. Al-Mansour received her medical degree from Jordan University of Science and Technology in Irbid, Jordan. She completed an internship in internal medicine at the University of New Mexico and her residency in internal medicine as well as a fellowship in hematology and oncology at the University of Massachusetts. She subsequently served as an assistant professor at the University of Massachusetts prior to joining UF Health.
After her post-graduate training, Dr. Al-Mansour soon began as an assistant professor in the Department of Internal Medicine at Loyola University Chicago. She also served as an assistant professor at the University of Massachusetts prior to joining UF Health. Dr. Al-Mansour is board certified with the American Board of Internal Medicine in both hematology and medical oncology in addition to general internal medicine.
Dr. Al-Mansour’s primary clinical interests focus on hematological malignancies and hematopoietic cell transplant, particularly transplant in the elderly population. She served on the University of Massachusetts’ medical school curriculum and admission committees, and she was selected to participate in the American Society of Hematology’s Medical Educators Institute, which awarded her a grant to develop tools for geriatric assessment in treating hematological malignancies.
Accomplishments
Communication Skills Physician Champion
2019-2020
·
UMass Memorial Medical Center/Ariadne Labs
Member
2019-2020
·
American Society of Hematology (ASH) Medical Educator Institute
Teaching Profile
Courses Taught
2022,2024
GMS6001 Fundamentals of Biomedical Sciences I
Board Certifications
-
American Board of Internal MedicineInternal Medicine
-
American Board of MedicineBoard of Hematology
-
American Board of MedicineMedical Oncology
Clinical Profile
Specialties
- Cancer
- Hematology and Oncology
Areas of Interest
- Acute myeloid leukemia – adult
- Bone marrow transplant
- Myelodysplastic Syndromes (MDS)
Research Profile
Open Researcher and Contributor ID (ORCID)
0000-0002-8125-703X
Areas of Interest
- Alternative donor options for HCT
- Health-related quality of life after HCT
- Hematopoietic Cell Transplant (HCT) in Elderly
- Med Ed: Optimizing Transplant & Cellular Therapy Education for Hematology/Oncology Fellows
- Psychosocial Interventions before and after HCT for the geriatric patient
Publications
2024
A phase ib clinical trial of oral ciprofloxacin and etoposide in subjects with resistant acute myeloid leukemia.
Leukemia & lymphoma.
1-9
[DOI] 10.1080/10428194.2024.2361111.
[PMID] 38841781.
2024
Global research productivity of post-transplant lymphoproliferative disorder: a bibliometric study.
Annals of medicine and surgery (2012).
86(3):1522-1530
[DOI] 10.1097/MS9.0000000000001771.
[PMID] 38463089.
2023
Entospletinib with decitabine in acute myeloid leukemia with mutant TP53 or complex karyotype: A phase 2 substudy of the Beat AML Master Trial.
Cancer.
129(15):2308-2320
[DOI] 10.1002/cncr.34780.
[PMID] 37078412.
2023
Health-Related Quality of Life Outcomes in Older Hematopoietic Cell Transplantation Survivors.
Transplantation and cellular therapy.
29(3):202.e1-202.e8
[DOI] 10.1016/j.jtct.2022.11.016.
[PMID] 36427784.
2023
Pericardial Effusion: A Novel Presentation of Aplastic Anemia.
Cureus.
15(1)
[DOI] 10.7759/cureus.33276.
[PMID] 36741642.
2022
Polygenic Ara-C Response Score Identifies Pediatric Patients With Acute Myeloid Leukemia in Need of Chemotherapy Augmentation.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
40(7):772-783
[DOI] 10.1200/JCO.21.01422.
[PMID] 34990262.
2022
Self-Efficacy for Symptom Management in Long-Term Adult Hematopoietic Stem Cell Survivors.
Transplantation and cellular therapy.
28(9):606.e1-606.e8
[DOI] 10.1016/j.jtct.2022.05.035.
[PMID] 35662590.
2021
Gut Microbiota Dysbiosis Associated with Persistent Fatigue in Hematopoietic Cell Transplantation Survivors.
Transplantation and cellular therapy.
27(6):498.e1-498.e8
[DOI] 10.1016/j.jtct.2021.02.017.
[PMID] 33775619.
2021
Immunotherapy Management in Special Cancer Patient Populations.
JCO oncology practice.
17(5):240-245
[DOI] 10.1200/OP.20.00996.
[PMID] 33710933.
2020
Baseline Gut Microbiota Composition Is Associated with Major Infections Early after Hematopoietic Cell Transplantation.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
26(11):2001-2010
[DOI] 10.1016/j.bbmt.2020.07.023.
[PMID] 32717434.
2019
Autologous transplantation as consolidation for high risk aggressive T-cell non-Hodgkin lymphoma: a SWOG 9704 intergroup trial subgroup analysis.
Leukemia & lymphoma.
60(8):1934-1941
[DOI] 10.1080/10428194.2018.1563691.
[PMID] 30628511.
2019
Novel Cancer Therapeutics in Geriatrics: What is Unique to the Aging Patient?
Drugs & aging.
36(1):1-11
[DOI] 10.1007/s40266-018-0619-2.
[PMID] 30478744.
2018
Hematopoietic Cell Transplant (HCT) in the Elderly: Myths, Controversies and Unknowns.
Drugs & aging.
35(12):1055-1064
[DOI] 10.1007/s40266-018-0596-5.
[PMID] 30302674.
2017
C-MYC-positive relapsed and refractory, diffuse large B-cell lymphoma: Impact of additional “hits” and outcomes with subsequent therapy.
Cancer.
123(22):4411-4418
[DOI] 10.1002/cncr.30895.
[PMID] 28749548.
2017
Diffuse large B-cell lymphoma with primary treatment failure: Ultra-high risk features and benchmarking for experimental therapies.
American journal of hematology.
92(2):161-170
[DOI] 10.1002/ajh.24615.
[PMID] 27880984.
2016
De novo CD5+ diffuse large B-cell lymphoma: Adverse outcomes with and without stem cell transplantation in a large, multicenter, rituximab treated cohort.
American journal of hematology.
91(4):395-9
[DOI] 10.1002/ajh.24299.
[PMID] 26800311.
2015
Gray zone lymphoma with features intermediate between classical Hodgkin lymphoma and diffuse large B-cell lymphoma: characteristics, outcomes, and prognostication among a large multicenter cohort.
American journal of hematology.
90(9):778-83
[DOI] 10.1002/ajh.24082.
[PMID] 26044261.
2014
Post-Autologous (ASCT) Stem Cell Transplant Therapy in Multiple Myeloma.
Advances in hematology.
2014
[DOI] 10.1155/2014/652395.
[PMID] 25525435.
2013
Post-transplant lymphoproliferative disease (PTLD): risk factors, diagnosis, and current treatment strategies.
Current hematologic malignancy reports.
8(3):173-83
[DOI] 10.1007/s11899-013-0162-5.
[PMID] 23737188.
2010
Locally advanced cervical cancer: what is the standard of care?
Current opinion in oncology.
22(5):503-12
[DOI] 10.1097/CCO.0b013e32833af426.
[PMID] 20473164.
Grants
Sep 2023
ACTIVE
Real-World Comparative Effectiveness of Belumosudil vs. Physician's Choice of Best Available Therapy for the Treatment of Chronic Graft vs. Host Disease: A Retrospective Cohort Study Using Patient Medical Records
Role: Principal Investigator
Funding: PAREXEL INTERNATIONAL PTY
via SANOFI US SERVICES
May 2023
– May 2024
Targeting medium chain fatty acid metabolism for the treatment of chronic Graftversus-Host Disease
Role: Principal Investigator
Funding: UNIV OF CENTRAL FLORIDA
via NATL INST OF HLTH NHLBI
Apr 2023
ACTIVE
Predicting Quality of Response to Specific Treatment (PQRST)
Role: Principal Investigator
Funding: FRED HUTCHINSON CANCER CENTER
via NATL INST OF HLTH NCI
Jul 2022
ACTIVE
Close Assessment and Testing for Chronic Graft-versus-Host Disease (The CATCH Study)- Cost Reimbursable
Role: Principal Investigator
Funding: FRED HUTCHINSON CANCER CENTER
via NATL INST OF HLTH NCI
Jul 2022
ACTIVE
Close Assessment and Testing for Chronic Graft-versus-Host Disease (The CATCH Study)- Fixed
Role: Principal Investigator
Funding: FRED HUTCHINSON CANCER CENTER
via NATL INST OF HLTH NCI
Jun 2022
ACTIVE
A Phase 1b Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of SER-155 in Adults Undergoing Hematopoietic Stem Cell Transplantation to Reduce the Risk of Infection and Graft vs. Host Disease
Role: Principal Investigator
Funding: MEDPACE
via SERES THERAPEUTICS
Apr 2022
ACTIVE
Predicting the Quality of Response to Specific Treatments (PQRST) *Cost Reimbursable*
Role: Principal Investigator
Funding: FRED HUTCHINSON CANCER CENTER
via NATL INST OF HLTH NCI
Apr 2022
ACTIVE
Predicting the Quality of Response to Specific Treatments (PQRST) *Fixed Fee*
Role: Principal Investigator
Funding: FRED HUTCHINSON CANCER CENTER
via NATL INST OF HLTH NCI
Sep 2021
ACTIVE
AGAVE-201, A Phase 2, Open-label, Randomized, Multicenter Study to Evaluate the Efficacy, Safety and Tolerability of Axatilimab at 3 Different Doses in Patients with Recurrent or Refractory Active Chronic Graft Versus Host Disease who have Received at least 2 Lines of Systemic Therapy
Role: Principal Investigator
Funding: MEDPACE
via SYNDAX PHARMACEUTICALS
Jul 2021
ACTIVE
Phase III Randomized Trial of DFP-10917 vs. Non-Intensive Reinduction (LoDAC, Azacitidine, Decitabine, Venetoclax Combination Regimens) or Intensive Reinduction (High and Intermediate Dose Cytarabine Regimens) for Acute Myelogenous Leukemia Patients in Second, Third, or Fourth Salvage
Role: Principal Investigator
Funding: DELTA-FLY PHARMA
Jul 2021
ACTIVE
A Multi-Center, Phase II Trial of HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide for Patients with Hematologic Malignancies
Role: Principal Investigator
Funding: NATL MARROW DONOR PROGRAM
Jan 2021
– Aug 2023
A Randomized, Open-Label Study of the Efficacy and Safety of Galinpepimut-S (GPS) Maintenance Monotherapy Compared to Investigator's Choice of Best Available Therapy in Subjects with Acute Myeloid Leukemia Who Have Achieved Complete Remission After Second-Line Salvage Therapy
Role: Principal Investigator
Funding: PPD INVESTIGATOR SERVICES LLC
via SELLAS LIFE SCIENCES
Oct 2019
– Jun 2023
A Master Protocol for Biomarker-Based Treatment of
AML (The Beat AML Trial)
Role: Principal Investigator
Funding: SYNEOS HEALTH
via LEUKEMIA & LYMPHOMA SOC
Education
Hematology/Oncology Fellowship
2012-2015
·
University of Massachusetts
Internal Medicine
2010-2012
·
University of Massachusetts Residency
University of New Mexico
2009-2010
·
Internal Medicine Internship
Medical Degree
2000-2006
·
Jordan University of Science & Technology – Irbid in Jordan
Contact Details
Phones:
- Business:
- (352) 273-7832
Emails:
- Business:
- zeina.almansour@ufl.edu
Addresses:
- Business Mailing:
-
PO Box 100278
GAINESVILLE FL 32610 - Business Street:
-
BIN #CO3
FL
1600 SW Archer Rd
Gainesville FL 32610